Market Access News | pharmaphorum

News

J&J adds to IL-23 options in Crohn's after FDA approval

J&J's Tremfya gets a much-anticipated FDA approval for Crohn's disease, which the company thinks will be key to a renewed phase of sales growth.

News

Alnylam joins three-way contest in ATTR cardiomyopathy

Alnylam has claimed FDA approval for Amvuttra in ATTR cardiomyopathy, allowing it to compete with rival therapies from Pfizer and BridgeBio.

News

UK is becoming an 'outlier' for pharma, hitting investment

UK pharma leaders have renewed calls for a rethink by the government on levies imposed on medicine sales, saying investment is already being hit.

News

J&J's nipocalimab fast-tracked for Sjogren's disease

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.

News

FDA chooses flu vaccine strains despite cancelled meeting

The FDA has released its recommendations on the composition of influenza vaccines for the 2025-26 season – without the input of its external advisors.

News

Pharma furious as UK Statutory Scheme rebate rate soars

The UK pharma sector has reacted with consternation to the government's proposal to raise the Statutory Scheme rate to 32.2% in the last half of 2025.

J&J adds to IL-23 options in Crohn's after FDA approval

Alnylam joins three-way contest in ATTR cardiomyopathy

UK is becoming an 'outlier' for pharma, hitting investment

J&J's nipocalimab fast-tracked for Sjogren's disease

FDA chooses flu vaccine strains despite cancelled meeting

Pharma furious as UK Statutory Scheme rebate rate soars

BMS eyes role for new CAR-T in post-BCMA multiple myeloma

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks